Inflammatory bowel disease and celiac disease: overlaps and differences.

Recent findings demonstrate the common genetic basis for many immune-mediated diseases, and consequently, the partially shared pathogenesis. We collected these findings and reviewed the extension of these overlaps to other disease characteristics. Two autoimmune diseases were selected that also share the specific target organ, the bowel. The etiology and immunopathogenesis of both conditions characterized by chronic intestinal inflammation, inflammatory bowel disease (IBD) and celiac disease (CeD), are not completely understood. Both are complex diseases with genetics and environment contributing to dysregulation of innate and adaptive immune responses, leading to chronic inflammation and disease. CeD constitutes a particular disease because the main environmental and genetic triggers are largely known. IBD comprises two main clinical forms, Crohn's disease and ulcerative colitis, which most likely involve a complex interplay between some components of the commensal microbiota and other environmental factors in their origin. These multifactorial diseases encompass a broad spectrum of clinical phenotypes and ages of onset, although the clinical presentation often differs depending on childhood or adult onset, with greater heterogeneity commonly observed in adults.

[1]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[2]  G. Holmes,et al.  Association of coeliac disease and inflammatory bowel disease. , 1980, Gut.

[3]  V. Annese,et al.  Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. , 2010, Digestive and Liver Disease.

[4]  A. Neugut,et al.  Characteristics of adult celiac disease in the USA: results of a national survey , 2001, American Journal of Gastroenterology.

[5]  Virgínia Lúcia Ribeiro-Cabral,et al.  Anti-tissue transglutaminase antibodies (IgA and IgG) in both Crohn´s disease and autoimmune diabetes. , 2011, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[6]  Sarah Edkins,et al.  Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease , 2011, Nature Genetics.

[7]  P. Adibi,et al.  Serologic celiac disease in patients with inflammatory bowel disease , 2012, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[8]  P. Lakatos,et al.  Smoking in inflammatory bowel diseases: good, bad or ugly? , 2007, World journal of gastroenterology.

[9]  A. Moss,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.

[10]  C. Mulder,et al.  Refractory coeliac disease. , 2005, Best practice & research. Clinical gastroenterology.

[11]  K. Giersiepen,et al.  European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease , 2012, Journal of pediatric gastroenterology and nutrition.

[12]  Donatella,et al.  A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease , 2011, PLoS genetics.

[13]  T. Hibi,et al.  Appendectomy protects against the development of ulcerative colitis and reduces its recurrence: results of a multicenter case-controlled study in Japan , 2001, American Journal of Gastroenterology.

[14]  M. Cottone,et al.  FAMILIAL ASSOCIATION OF CROHN'S AND COELIAC DISEASES , 1989, The Lancet.

[15]  B. Dema,et al.  Th17-Related Genes and Celiac Disease Susceptibility , 2012, PloS one.

[16]  L. Greco,et al.  The first large population based twin study of coeliac disease , 2002, Gut.

[17]  M. Olandoski,et al.  Antibodies anti-Saccharomyces cerevisiae (ASCA) do not differentiate Crohn's disease from celiac disease. , 2010, Arquivos de gastroenterologia.

[18]  C. Åhrén,et al.  Chronic inflammatory bowel disease in patients with coeliac disease. , 1982, Scandinavian journal of gastroenterology.

[19]  P. Rutgeerts,et al.  Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[20]  C. Neut,et al.  Dysbiosis as a prerequisite for IBD. , 2004, Gut.

[21]  K. Kaukinen,et al.  The Duodenal Microbiota Composition of Adult Celiac Disease Patients Is Associated with the Clinical Manifestation of the Disease , 2013, Inflammatory bowel diseases.

[22]  Jorma Ilonen,et al.  Prevalence of Celiac disease among children in Finland. , 2003, The New England journal of medicine.

[23]  D. Coggon,et al.  Inflammatory bowel disease and domestic hygiene in infancy , 1994, The Lancet.

[24]  J. Hugot,et al.  Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. , 2005, Journal of pediatric gastroenterology and nutrition.

[25]  A. Tursi,et al.  High Prevalence of Celiac Disease Among Patients Affected by Crohn's Disease , 2005, Inflammatory bowel diseases.

[26]  J. Murray,et al.  Review article: coeliac disease, new approaches to therapy , 2012, Alimentary pharmacology & therapeutics.

[27]  Jaume Bertranpetit,et al.  A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300 , 2012, Gut.

[28]  B. Messing,et al.  A severe but reversible refractory sprue , 2005, Gut.

[29]  A. Neugut,et al.  Inflammatory Bowel Disease in Patients with Celiac Disease , 2005, Inflammatory bowel diseases.

[30]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[31]  P. Green,et al.  Epidemiology and clinical presentations of celiac disease , 2012, Seminars in Immunopathology.

[32]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[33]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[34]  L. Fugger,et al.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease , 1998, Nature Medicine.

[35]  S. Ng,et al.  Characterization of the Gastrointestinal Microbiota in Health and Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[36]  C. Mulder,et al.  Azathioprine and prednisone combination therapy in refractory coeliac disease , 2003, Alimentary pharmacology & therapeutics.

[37]  L. Ciobanu,et al.  Unknown complicated celiac disease as an unexpected finding in patients investigated with capsule endoscopy for Crohn's disease. A case series. , 2013, Journal of gastrointestinal and liver diseases : JGLD.

[38]  L. Nyström,et al.  The Swedish coeliac disease epidemic with a prevailing twofold higher risk in girls compared to boys may reflect gender specific risk factors , 2002, European Journal of Epidemiology.

[39]  M. Ament,et al.  Celiac sprue and Crohn's disease: an association causing severe growth retardation. , 1977, Gastroenterology.

[40]  E. Seidman,et al.  Guideline for the Diagnosis and Treatment of Celiac Disease in Children : Recommendations of the North American Society for Pediatric Gastroenterology , Hepatology and Nutrition , 2004 .

[41]  E. Macintyre,et al.  Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma , 2000, The Lancet.

[42]  A. Doria,et al.  IgA and IgG Tissue Transglutaminase Antibody Prevalence and Clinical Significance in Connective Tissue Diseases, Inflammatory Bowel Disease, and Primary Biliary Cirrhosis , 2003, Digestive Diseases and Sciences.

[43]  B. V. von Blomberg,et al.  Cladribine therapy in refractory celiac disease with aberrant T cells. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  H. Freeman,et al.  Celiac disease: prevalence, diagnosis, pathogenesis and treatment. , 2012, World journal of gastroenterology.

[45]  A. Caminero,et al.  Differences of small intestinal bacteria populations in adults and children with/without celiac disease: Effect of age, gluten diet, and disease , 2012, Inflammatory bowel diseases.

[46]  G. Martorana,et al.  Familial occurrence of inflammatory bowel disease in celiac disease. , 2003 .

[47]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[48]  J. Dahm,et al.  [Celiac disease in the adult--a case report]. , 1991, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

[49]  C. Lowry,et al.  Hygiene and other early childhood influences on the subsequent function of the immune system , 2012, Brain Research.

[50]  A. Salas,et al.  The prevalence of coeliac disease is significantly higher in children compared with adults , 2011, Alimentary pharmacology & therapeutics.

[51]  O. Lohi,et al.  Increasing prevalence of coeliac disease over time , 2007, Alimentary pharmacology & therapeutics.

[52]  J. Cosnes Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. , 2004, Best practice & research. Clinical gastroenterology.

[53]  A. Ananthakrishnan Environmental risk factors for inflammatory bowel disease. , 2013, Gastroenterology & hepatology.

[54]  K. Helzlsouer,et al.  Natural history of celiac disease autoimmunity in a USA cohort followed since 1974 , 2010, Annals of medicine.

[55]  G. Lichtenstein Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial , 2008 .

[56]  D. MacArthur,et al.  Negligible impact of rare autoimmune-locus coding-region variants on missing heritability , 2013, Nature.

[57]  V. Kuchroo,et al.  Induction and effector functions of TH17 cells , 2008, Nature.

[58]  C. Catassi [The global village of celiac disease]. , 2008, Recenti progressi in medicina.

[59]  W. Verbeek,et al.  The Management of Complicated Celiac Disease , 2007, Digestive Diseases.

[60]  D. Jewell,et al.  Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease , 1996, The Lancet.

[61]  Cisca Wijmenga,et al.  A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease , 2011, PLoS genetics.

[62]  Giuseppe Leone,et al.  Environmental risk factors for MDS/AML , 2009 .

[63]  B. Božič,et al.  Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value , 2010, Wiener klinische Wochenschrift.

[64]  R. Sartor The influence of normal microbial flora on the development of chronic mucosal inflammation. , 1997, Research in immunology.

[65]  Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. , 2005, Archives of disease in childhood.

[66]  D. Ardid,et al.  Immunopathogenesis of inflammatory bowel disease. , 2010, Self/nonself.

[67]  P. Marques‐Vidal,et al.  Impact of Disease and Treatments on Growth and Puberty of Pediatric Patients with Inflammatory Bowel Disease , 2012, Digestion.

[68]  S. Montgomery,et al.  Increasing Incidence of Paediatric Inflammatory Bowel Disease in Northern Stockholm County, 2002–2007 , 2013, Journal of pediatric gastroenterology and nutrition.

[69]  A. Amiot,et al.  Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. , 2009, Gastroenterology.

[70]  D. Jewell,et al.  Role of the faecal stream in the maintenance of Crohn's colitis. , 1985, Gut.

[71]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[72]  G. Raimondo,et al.  Celiac Disease and Non-organ-specific Autoantibodies in Patients with Chronic Hepatitis C Virus Infection , 2008, Digestive Diseases and Sciences.

[73]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[74]  E. Loftus Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[75]  R. Panaccione,et al.  Review: Efficacy and safety of adalimumab in Crohn's disease , 2008, Therapeutic advances in gastroenterology.

[76]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[77]  C. Elson,et al.  Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota , 2005, Immunological reviews.

[78]  Y. Sanz,et al.  Unraveling the Ties between Celiac Disease and Intestinal Microbiota , 2011, International reviews of immunology.

[79]  Lu Shan,et al.  Structural Basis for Gluten Intolerance in Celiac Sprue , 2002, Science.

[80]  E. Lindberg,et al.  Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. , 2003, Gastroenterology.

[81]  H. Freeman Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[82]  M. Rewers,et al.  Rotavirus Infection Frequency and Risk of Celiac Disease Autoimmunity in Early Childhood: A Longitudinal Study , 2006, The American Journal of Gastroenterology.

[83]  J. Scolapio,et al.  Increased Prevalence and Mortality in Undiagnosed Celiac Disease , 2009 .

[84]  S. Ghosh,et al.  Serum IgA tissue transglutaminase antibodies in coeliac disease and other gastrointestinal diseases. , 2001, QJM : monthly journal of the Association of Physicians.

[85]  A. Schäffer,et al.  Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.

[86]  J. Murray,et al.  Prevalence of Celiac Disease in At-Risk and Not-At-Risk Groups in the United States , 2003 .

[87]  J. Schulzke,et al.  Randomized, Double Blind Controlled Trial of Subcutaneous Recombinant Human Interleukin-11 Versus Prednisolone in Active Crohn's Disease , 2006, The American Journal of Gastroenterology.

[88]  D. Schuppan,et al.  Monitoring nonresponsive patients who have celiac disease. , 2006, Gastrointestinal endoscopy clinics of North America.

[89]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.